Quantum BioPharma (NASDAQ: QNTM) has reported unaudited financial and operational results for the third quarter ended Sept. 30, 2026, revealing a strengthened balance sheet and progress in its clinical development program. The company's cash and digital assets totaled $12.22 million, a significant increase from $4.12 million at year-end 2025, excluding restricted digital assets. This improved liquidity, alongside a 91% rise in shareholders' equity to $9.77 million and working capital of $5.47 million (up from $420,000), underscores the company's ability to fund its planned operations over the next 12 months.
The financial improvement is accompanied by a 24% year-over-year decline in third-quarter operating expenses to $3.56 million and a 26% narrowing of the nine-month net loss to $17.32 million from $23.25 million. Quantum also reduced its operating cash use by 21% for the first nine months of 2026 and decreased notes payable to $300,000 after repaying $1 million in debt. These metrics suggest a more efficient cost structure as the company prioritizes its clinical programs.
Central to those programs is Lucid-MS, a patented new chemical entity designed to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Following FDA clearance of its Investigational New Drug application in August 2026, Quantum entered into a study start-up agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 trial of Lucid-MS for progressive multiple sclerosis. This agreement marks a critical operational step toward initiating patient enrollment and generating the data needed to advance the candidate.
The implications are substantial. Progressive multiple sclerosis remains an area with limited treatment options, and a therapy that targets myelin repair could address a significant unmet need. For Quantum, the trial's success could validate its platform and open partnership or licensing opportunities. The company's financial position, with sufficient cash and digital assets to support planned operations, reduces near-term financing risk and allows management to focus on execution. Investors can find the full press release at https://ibn.fm/GJ1ER and review the original release on www.newmediawire.com.
Quantum BioPharma's pipeline also includes UNBUZZD(TM), an OTC product spun out to Unbuzzd Wellness Inc., in which Quantum retains a 19.84% ownership stake and a 7% royalty on sales until payments reach $250 million, thereafter dropping to 3% in perpetuity. While the company retains 100% of rights to develop similar products for pharmaceutical and medical uses, the primary near-term value driver is Lucid-MS. The Phase 2 trial's progress will be closely watched, as positive results could transform the treatment landscape for progressive MS and significantly enhance Quantum's strategic position.
For ongoing updates on Quantum BioPharma, visit the company's newsroom at https://ibn.fm/QNTM. Full terms of use and disclaimers applicable to all content provided by IBN are available at https://IBN.ai/Disclaimer.


